Whitepaper: USP method modernisation
Posted: 8 December 2021 | Thermo Fisher Scientific | No comments yet
The incorporation of IC to the USP offers a great potential to reduce the number of tests from five to two and significantly simplify any such monograph. Such opportunities not only offer analysts a significant reduction in the number of tests but also introduce the reliability and reproducibility required in a modern GMP laboratory, namely retention time reproducibility, time and cost savings, and overall reduction in user training and system maintenance needs.
Related content from this organisation
- ebook: Twin-screw extrusion for pharmaceutical applications
- Biopharmaceuticals contributing to manufacturing outsourcing trend
- Biologics driving continuous bioprocessing market expansion
- Mycoplasma testing market expected to value nearly $2 million by 2031
- Drug development trends: insight from Thermo Fisher’s Anil Kane
Related topics
Analytical techniques, Biologics, Biopharmaceuticals, Chromatography, Data integrity, Drug Delivery Systems, Excipients, Formulation, Good Manufacturing Practice (GMP), Ingredients, Lab Automation, Manufacturing, Outsourcing, QA/QC, Regulation & Legislation, Research & Development (R&D)